| Illumina–Roche: genomic cancer testing, 202001–201412 collab €na strategic alliance non-excl for NGS-based cancer testing for IVD + CDx |
2020-01-13 |
| Incyte–MorphoSys: tafasitamab, 202001– collab + ww excl license incl US co-commercialisation $750m upfront + $1.1b milestones |
2020-01-13 |
| MorphoSys–Incyte: investment, 202001 equity investment $150m in new ADSs at premium to share price as part of tafasitamab collab/license agreement |
2020-01-13 |
| NBE Therapeutics–Boehringer: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor BIVF |
2020-01-10 |
| NBE Therapeutics–OTHER: investment, 202001 financing round Series C USD22m incl all existing private shareholders |
2020-01-10 |
| NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group |
2020-01-10 |
| NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C USD22m led by existing investors BIVF + PPF Group wih all private investors |
2020-01-10 |
| Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi |
2020-01-09 |
| Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
| Wellington Partners–MC Services: public relations, 202001 service existent by MC Services |
2020-01-08 |
| Boehringer–PhoreMost: drug discovery services, 202001– collab €na multi-project target discovery using Siteseeker platform |
2020-01-07 |
| VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors |
2020-01-07 |
| VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative |
2020-01-07 |
| VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings |
2020-01-07 |
| VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors |
2020-01-07 |
| VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures |
2020-01-07 |
| VectivBio–WPP: public relations, 202001 service existent by Glover Park Group |
2020-01-07 |
| Velabs Therapeutics–Alytas Therapeutics: therapeutic antibodies, 202001– license excl for developm + commercialisation of Abs in field of senescence |
2020-01-07 |
| Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc |
2019-12-20 |
| Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors |
2019-12-20 |
| CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance |
2019-12-19 |
| Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies |
2019-12-19 |
| Kinnate Biopharma–Nextech Invest: investment, 201912 financing round Series B totalling $74.5m incl new investor Nextech Invest Ltd |
2019-12-19 |
| Kinnate Biopharma–SEVERAL: investment, 201912 financing round Series B $74.5m from OrbiMed + Nextech Invest + Vida Ventures + Foresite + Eshelman |
2019-12-19 |
| Promega–Merck (DE): CRISPR technology, 201912– license to CRISPR IP io from Merck to Promega to develop CRISPR-edited cell lines |
2019-12-19 |
| BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi |
2019-12-18 |
| Cellestia Biotech–SEVERAL: investment, 201912 financing round Series B CHF20m from FC Capital + PPF Group + Partners Investment + private investors |
2019-12-17 |
| Resistell–SEVERAL: investment, 201912 financing round Series A CHF3.5m |
2019-12-17 |
| Abcalis–Germany (govt): grant, 201912 EXIST research transfer grant for founding from BMWi (plus ESF grant) |
2019-12-10 |
| ImmunOs Therapeutics–SEVERAL: investment, 201912 financing round Series CHF15m co-led by Pfizer Ventures + BioMedPartners |
2019-12-10 |
| Schauenburg–JP Scientific: SPE technology, 201912– ww commercial license + supply to Markes from JP Scientific Ltd |
2019-12-10 |
| Algiax Pharmaceuticals–SEVERAL: investment, 201912 financing round €5.5m incl new investor Occident |
2019-12-09 |
| EMBL–Bruker: microscope, 201912 supply existent early customer EMBL for new Luxendo TruLive3D Imager |
2019-12-09 |
| Synthorx–Sanofi: investment, 201912– acquisition $2.35b cash tender offer at $68/share ANNOUNCED |
2019-12-09 |
| BC Platforms–Scius Communications: public relations, 201912 supply service existent by Scius Communications |
2019-12-06 |
| Life & Brain–BC Platforms: genomic software tools, 201912– collab using BC Platforms solutions for genotyping services |
2019-12-06 |
| 4Teen4 Pharmaceuticals–Brandenburg (govt): investment, 201912 financing round Series A totalling €6.9m incl lead investor Brandenkapital GmbH |
2019-12-05 |
| 4Teen4 Pharmaceuticals–SEVERAL: investment, 201912 financing round Series A €6.9m led by Brandenkapital GmbH with private investors + business angels |
2019-12-05 |
| Biological Industries (IL)–Sartorius: investment, 201912 acquisition of just over 50% for €45m in cash with option to acquire further 20% |
2019-12-05 |
| ImCheck Therapeutics–Dentons: legal services, 201912 supply service Dentons Europe acted as legal counsel for €48m Series B round of ImCheck |
2019-12-04 |
| ImCheck Therapeutics–SEVERAL: investment, 201912 financing round Series B €48m co-led by Bpifrance + Pfizer Ventures |
2019-12-04 |
| ImCheck Therapeutics–Trophic Communications: public relations, 201912 service existent IR + PR US + EU by Trophic |
2019-12-04 |
| ImCheck Therapeutics–Wellington Partners: investment, 201912 financing round Series B totalling €48m incl new + co-investor Wellington Partners |
2019-12-04 |
| Indivumed–Biognosys: MS-based proteomics, 201912– collab integration of HRM MS proteomics data into multi-omics IndivuType cancer database |
2019-12-02 |
| Innate Pharma–Rentschler: biologics contract manufacturing, –201912 supply service production lacutamab for clinical trials |
2019-12-02 |
| ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB |
2019-11-29 |
| ViGeneron–MC Services: public relations, 201911 service existent media + investor relations by MC Services |
2019-11-28 |
| ViGeneron–Sequoia Capital: investment, 201911 financing round Series A incl co-lead investor Sequoia Capital China |
2019-11-28 |
| ViGeneron–SEVERAL: investment, 201911 financing round Series A co-led by WuXi AppTec + Sequoia Capital China |
2019-11-28 |
| ViGeneron–WuXi PharmaTech: investment, 201911 financing round Series A incl co-lead investor WuXi AppTec |
2019-11-28 |
| MaxiVax–EU (govt): grant, 201911 Horizon 2020 EIC Accelerator grant €2.785m |
2019-11-26 |
| MaxiVax–SEVERAL: investment, 201911 financing round Series B2 CHF5m from existing + new investors |
2019-11-26 |
| Single Use Support–SHS: investment, 201911 investment by SHS Gesellschaft für Beteiligungsmanagement within framework of capital increase |
2019-11-26 |
| Ferring–Blackstone: investment, 201911– investment $400m by Blackstone Life Sciences in FerGene to develop + market nadofaragene firadenovec |
2019-11-25 |
| Medicines Company–Novartis: investment, 201911– cash tender offer $9.7b at $85/share ANNOUNCED |
2019-11-24 |
| Immunitas Therapeutics–Bayer: investment, 201911 financing round Series A totalling $39m incl co-lead investor Leaps by Bayer |
2019-11-21 |
| Immunitas Therapeutics–Evotec: investment, 201911 financing round Series A totalling $39m incl co-investor Evotec |
2019-11-21 |
| Immunitas Therapeutics–Merck (DE): investment, 201911 financing round Series A totalling $39m incl co-investor M Ventures |
2019-11-21 |
| Immunitas Therapeutics–Novartis: investment, 201911 financing round Series A totalling $39m incl co-lead investor Novartis Venture Fund |
2019-11-21 |
| Immunitas Therapeutics–SEVERAL: investment, 201911 financing round Series A $39m co-led by Leaps by Bayer + Novartis Venture Fund |
2019-11-21 |
| LabCorp–Qiagen: bioinformatics, 201911– license extension with HGMD in addition ot Qiagen Clinical Insights |
2019-11-20 |
| Causaly–SEVERAL: investment, 201911 financing round Series A $5m led by Pentech Ventures + incl EBRD VC + Marathon VC et al. |
2019-11-19 |
| CRISPR Therapeutics–SEVERAL: investment, 201911 public offering up to $315.25m with 4.25m+637.5k common shares at $64.5/share |
2019-11-19 |
| Kuros–SEVERAL: investment, 201911–201912 capital increase CHF12.5m with 6.405m new registered shares at CHF1.95/share |
2019-11-19 |
| Novartis–Causaly: Natural Language Processing s/w, 201911 collab existent |
2019-11-19 |
| Rodin Therapeutics–Alkermes: investment, 201911 acquisition $100m upfront cash + $850m milestones by Alkermes |
2019-11-18 |
| Turbine–Atlantic Labs: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Atlantic Labs Manager GmbH |
2019-11-13 |
| Turbine–Delin Ventures: investment, 201911 first institutional financing round totalling €3m incl lead investor Delin Ventures |
2019-11-13 |
| Turbine–o2h: investment, 201911 first institutional financing round totalling €3m incl new + co-investor o2h Ventures |
2019-11-13 |
| Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Esther Dyson |
2019-11-13 |
| Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Vishal Gulati |
2019-11-13 |
| Turbine–SEVERAL: investment, 201911 first institutional financing round €3m led by Delin Ventures + incl Atlantic Labs et al. |
2019-11-13 |
| Evotec–Merck (DE): CRISPR technology, 201911– license to CRISPR IP portfolio from Merck to Evotec |
2019-11-12 |
| Immatics–Genedata: bioinformatics, 201911– license to Genedata Biologics for use with Xceptor TCR discovery + engineering platform |
2019-11-12 |
| NEC–Vaximm: cancer vaccines, 201911– collab + option agreem for personalised neoantigen cancer vaccines |
2019-11-12 |
| Vaximm–NEC: investment, 201911 equity investment by NEC in connection with collab + option agreem |
2019-11-12 |
| Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED |
2019-11-11 |
| eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer |
2019-11-07 |
| eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners |
2019-11-07 |
| Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform |
2019-11-07 |
| Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA |
2019-11-06 |
| Vifor Pharma–Evotec: drug r+d, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w |
2019-11-06 |
| Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners |
2019-11-04 |
| Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners |
2019-11-04 |
| Saniva Diagnostics–Xlife Sciences: investment, 201911 investment by Xlife Sciences AG in Saniva Diagnostics GmbH |
2019-11-04 |
| Roivant–Sumitomo: investment, 201910 acquisition 10% stake in Roivant by Sumitomo Dainippon Pharma in connection w strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Altavant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Enzyvant Therapeutics by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Myovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Spirovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Urovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma |
2019-10-31 |
| AstraZeneca–BBG/Braun Group: quetiapine fumarate, 201910– acquisition $178m upfront + up to $61m rights to Seroquel/XR in Europe + RU by Cheplapharm |
2019-10-30 |
| Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market |
2019-10-28 |
| OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m |
2019-10-23 |
| MCG Motion Capture–Akampion: public relations, 201910 service existent by Akampion |
2019-10-22 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
